Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID-19 in patients with chronic liver disease

Lukas Hartl1,2 | Katharina Haslinger1,2 | Martin Angerer1,2 | Georg Semmler1,2 | Mathias Schneeweiss-Gleixner1 | Mathias Jachs1,2 | Benedikt Simbrunner1,2,3 | David Josef Maria Bauer1,2 | Ernst Eigenbauer4 | Robert Strassi5 | Monika Breuer5 | Oliver Kimberger6 | Daniel Laxar6 | Katharina Lampichler7 | Emina Halilbasic1 | Albert Friedrich Stättermayer1,2 | Ahmed Ba-Ssalamah7 | Mattias Mandorfer1,2 | Bernhard Scheiner1,2 | Thomas Reiberger1,2,3 | Michael Trauner1

1Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
2Vienna Hepatic Hemodynamic Lab, Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria
3Christian Doppler Lab for Portal Hypertension and Liver Fibrosis, Medical University of Vienna, Vienna, Austria
4IT-Systems and Communications, Medical University of Vienna, Vienna, Austria
5Division of Clinical Virology, Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria
6Department of Anaesthesia, Intensive Care Medicine and Pain Medicine, Medical University of Vienna, Vienna, Austria
7Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria

Correspondence
Thomas Reiberger, Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
Email: thomas.reiberger@meduniwien.ac.at

Abstract

Background and Aims: Cholestasis is associated with disease severity and worse outcome in COVID-19. Cases of secondary sclerosing cholangitis (SSC) after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have been described.

Approach and Results: Hospitalized patients with COVID-19 between 03/2020 and 07/2021 were included. Patients were stratified as having (i) no chronic liver disease (CLD), (ii) non-advanced CLD (non-ACLD), or (iii) advanced CLD (ACLD). Patients with CLD and non-COVID-19 pneumonia were matched to patients with CLD and COVID-19 as a control cohort. Liver chemistries before (Pre) and at first, second, and third blood withdrawal after SARS-CoV-2 infection (T1–T3) and at last available time point (last) were recorded. A total of 496 patients were included. In total, 13.1% (n = 65) had CLD (non-ACLD: 70.8%; ACLD: 29.2%); the predominant etiology was NAFLD/NASH (60.0%). COVID-19-related liver injury was more common among patients with CLD (24.6% vs. 10.6%; p = 0.001). After SARS-CoV-2 infection, patients with CLD exhibited progressive cholestasis with persistently increasing levels of alkaline phosphatase (Pre: 91.0 vs. T1: 121.0 vs. last: 175.0 U/L; p < 0.001) and gamma-glutamyl transferase (Pre: 95.0 vs. T1: 135.0 vs. last: 202.0 U/L; p = 0.001). A total of 23.1% of patients
INTRODUCTION

Severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2), causes considerable morbidity and mortality globally. COVID-19 is an infectious disease affecting the respiratory, hepatic, neuronal and intestinal system, oftentimes leading to multiorgan failure and acute respiratory distress syndrome (ARDS). Among others, old age, obesity, male sex, and pre-existing comorbidities are known to be risk factors for mortality due to COVID-19.

Viral particles were detected in the cytoplasm of hepatocytes in liver biopsies of patients with SARS-CoV-2 infection, directly linking COVID-19–associated liver injury with hepatocellular infection. Moreover, SARS-CoV-2 is capable of infecting cholangiocytes in vitro. Apart from SARS-CoV-2-mediated cytotoxicity, other factors that may contribute to COVID-19–associated liver injury are the excessive proinflammatory state, coagulopathy-associated vascular dysfunction, drug-induced liver injury, hypoxemia and cardiac congestion likely all contribute to COVID-19–associated liver injury.

Liver chemistry abnormalities are known to occur in a substantial number of patients with COVID-19. Importantly, liver enzyme elevations were observed more frequently in patients who were critically ill and patients with severe courses of COVID-19. Initially, elevated levels of aspartate aminotransferase (AST) and bilirubin were established as independent predictors of COVID-19–associated mortality, indicating the clinical relevance of elevated liver chemistries in patients with SARS-CoV-2 infection. Although aminotransferase elevation is common early during COVID-19, cholestatic liver injury parameters increase in later stages of the disease. Cholestatic enzyme patterns and even progressive cholestatic liver failure with development of secondary sclerosing cholangitis (SSC) after severe SARS-CoV-2 infection have been reported, in some cases even requiring liver transplantation.

Conclusions: About 20% of patients with CLD develop progressive cholestasis after SARS-CoV-2 infection. Patients with NAFLD/NASH and metabolic risk factors are at particular risk for developing cholestatic liver failure and/or SSC after COVID-19.

PATIENTS AND METHODS

Study Population

This retrospective study included adult patients hospitalized for COVID-19 with positive SARS-CoV-2 test at the Vienna General Hospital between 03/2020 and 07/2021. Clinical and laboratory parameters, including preexisting CLD or ACLD, age, body mass index (BMI), comorbidities (i.e., preexisting diabetes mellitus, arterial hypertension, hyperlipidemia, as well as lung, cardiovascular, chronic kidney and malignant disease), hepatic decompensation events (portal hypertensive bleeding, paracentesis, hepatic encephalopathy), liver chemistries (AST, alanine aminotransferase [ALT], alkaline phosphatase [ALP], gamma-glutamyl transferase [GGT], and total

Funding information

Medical Scientific Fund of the Mayor of the City of Vienna, Grant/Award Number: MA 40-GMWF-185569-2020
bilirubin), hemoglobin, white blood cell count, platelet count, D-dimer, international normalized ratio, creatinine, serum sodium, albumin and C-reactive protein, hospital and intensive care unit (ICU) admission, as well as intubation, death, COVID-19–related death and liver-related death were assessed by chart review. Definitions for (A)CLD, liver-related death and COVID-19–related death are provided in the supplementary material. Patients without hospital admission or available data on the presence of CLD were excluded from the study (Figure S1). Notably, due to the retrospective design of the study, not all parameters were available for every patient. Patients were stratified for presence of CLD and presence of ACLD.

Control cohort of patients with CLD and non–COVID-19 pneumonia

In order assess a potential distinct effect of COVID-19 in patients with CLD, the clinical outcomes of these patients were compared to a control cohort of patients with CLD and non–COVID-19 pneumonia. The cohorts were matched for liver disease severity (i.e., non-ACLD, compensated ACLD [cACLD], and decompensated ACLD [dACLD]) and other key characteristics (see Supporting Material).

Laboratory parameters

All parameters were assessed by standard laboratory assays. The last available value prior to first positive SARS-CoV-2 PCR test (Pre), the first three available values after first positive SARS-CoV-2 PCR test (T1, T2 and T3, respectively) and the last available value (last) were recorded for each patient.

Local laboratory thresholds for men and women were implemented as upper limit of normal (ULN) for parameters of hepatocellular (AST and ALT) and cholestatic liver injury (ALP, GGT, and bilirubin). The definition of COVID-19–related liver injury is provided in the supplementary methods.

Severe cholestasis, cholestatic liver failure, and SSC

Severe cholestasis was defined as ALP/GGT >5× ULN and cholestatic liver failure was defined as presence of severe cholestasis and BIL ≥6 mg/dl. SSC was defined as presence of SSC-specific bile duct alterations or liver abnormalities (see Supporting Methods) in cross-sectional imaging or in endoscopic retrograde cholangiopancreatography (ERCP).

Statistical analysis

For categorical variables, the number (n) and proportion (%) of patients displaying the parameter of interest were reported. The total number of available values (n total) was added where appropriate. Continuous data was reported as median with interquartile range (IQR). Shapiro–Wilk and D’Agostino & Pearson normality tests were used to test for normal distribution. Mann–Whitney U test was implemented for comparison of non-normally distributed continuous variables between two groups. Kruskal-Wallis test was computed for comparison of non-normally distributed continuous variables in three or more groups. Dunn’s multiple comparisons test was used as post-hoc test. Fisher’s exact test or Pearson’s Chi-squared were used for group comparisons of categorical variables. Differences in survival between groups of elevated versus nonelevated levels of the parameters of interest were depicted by Kaplan–Meier curves. Log-rank test was used to determine differences in survival between these groups. Cox proportional hazard models were computed to assess the impact of the parameters of interest on (liver-related) mortality. Further information on the Cox proportional hazard models is provided in the supplementary methods. GraphPad Prism 8 (Graphpad Software, La Jolla, CA, USA) and IBM SPSS 22.0 statistic software (IBM, Armonk, NY) were used for statistical analysis. A two-sided p value of <0.05 was considered statistically significant.

RESULTS

Patient characteristics of patients with CLD and COVID-19 (Table 1)

In total, 496 patients with COVID-19 and associated hospital admission (normal bed ward: 59.1% [n = 293]; ICU: 40.9% [n = 203]) were included in this study. A total of 58.9% of patients were male. The median age was 67.4 (IQR 27.5) years. In total, 13.1% (n = 65) of included patients had preexisting CLD, including 19 (29.2%) patients with ACLD, 7 (36.8%) of whom were decompensated before the SARS-CoV-2 infection. The main etiology was NAFLD/NASH (60.0% of patients with CLD), followed by alcohol-associated liver disease (ALD; 15.4% of patients with CLD) and viral hepatitis (7.7% of patients with CLD). The frequency of specific CLD etiologies did not differ significantly between patients with and without ACLD. Further information on patient characteristics of patients with and without CLD with COVID-19 as well as of patients with CLD and non–COVID-19 pneumonia are provided in the supplementary results.
PROGRESSIVE CHOLESTASIS AND ASSOCIATED SCLEROSING CHOLANGITIS

Trajectory of liver chemistries in patients with CLD who tested positive for SARS-CoV-2 (Figure 1, Table S2)

Over the course of the SARS-CoV-2 infection in patients with CLD, there was an elevation of aminotransferases (AST: Pre: 26.5 U/L vs. T1: 46.5 U/L vs. last: 37.0 U/L, p < 0.001; ALT: Pre: 25.0 U/L vs. T1: 30.0 U/L vs. last: 36.0 U/L, p = 0.080), followed by a progressive increase of parameters of cholestatic liver injury (ALP: Pre: 91.0 U/L vs. T1: 119.0 U/L vs. last: 175.0 U/L, p < 0.001; GGT: p < 0.001). Although plasma levels of AST declined at the last available time point, GGT and especially ALP levels showed a steady increase during SARS-CoV-2 infection, which continued until the last available value, indicating a progressive state of cholestasis. Of note, this sustained ALP elevation in patients with CLD was visible even after excluding the patients, who developed SSC (Pre: 92.0 U/L vs. T1: 121 U/L vs. last: 138 U/L; p = 0.047). Although there was no significant difference in median levels of bilirubin during SARS-CoV-2 infection (p = 0.813), the rate of patients with bilirubin >2× ULN doubled over time (BIL >2× ULN: Pre: 9.2% vs. T1: 10.8% vs. last: 21.5%, p = 0.086).

In patients without CLD, the same pattern of liver enzyme elevation was present with significant AST/ALT elevation during early stages of COVID-19 (T1 to T3) and subsequently decrease to normal levels (last), whereas there was a steady increase of parameters of cholestatic liver injury with significant elevation of ALP at the time of last available values (Table S3).

Information on prevalence of COVID-19–related liver injury in patients with and without CLD is provided in the Supporting Material.

Clinical outcomes of patients with liver disease compared with patients without liver disease with COVID-19 (Table S1)

Median follow-up time was 34.5 (IQR 107.0) days. The rate of ICU admissions (p = 0.886), intubation

### Table 1

| Patient characteristics | Patients with liver disease (n = 65) | Patients without ACLD (n = 46) | Patients with ACLD (n = 19) | p value |
|-------------------------|--------------------------------------|--------------------------------|----------------------------|---------|
| Sex, male/female (% male) | 39/26 (60.0%) | 26/20 (56.5%) | 13/6 (68.4%) | 0.373 |
| Age, years (IQR) | 67.7 (19.6) | 70.3 (20.4) | 67.6 (19.8) | 0.641 |
| Etiology | | | | 0.172 |
| NAFLD/NASH, n (%) | 39 (60.0%) | 31 (67.4%) | 8 (42.1%) |
| ALD, n (%) | 10 (15.4%) | 4 (8.7%) | 6 (31.6%) |
| Viral hepatitis, n (%) | 5 (7.7%) | 3 (6.5%) | 2 (10.5%) |
| Crypto genetic, n (%) | 3 (4.6%) | 2 (4.3%) | 1 (5.3%) |
| Other, n (%) | 8 (12.3%) | 6 (13.0%) | 2 (10.5%) |
| Decompensated ACLD, n (%) | 7 (10.8%) | 0 (−) | 7 (36.8%) | 0.432 |
| MELD, points (IQR) | 9.0 (7.0) | 8.5 (10.0) | 10.0 (6.0) |
| COVID-19–related liver injury, n (%) | 14 (21.5%) | 9 (19.6%) | 5 (26.3%) | 0.547 |
| Median hospital stay, days (IQR) | 25.0 (40.0) | 27.0 (41.0) | 21.0 (39.0) | 0.641 |
| ICU admission, n (%) | 28 (43.1%) | 21 (45.7%) | 7 (36.8%) | 0.514 |
| Median ICU stay, days (IQR) | 24.5 (52.0) | 28.0 (60.0) | 20.0 (32.0) | 0.385 |
| Intubation, n (%) | 25 (38.5%) | 19 (41.3%) | 6 (31.6%) | 0.464 |
| Median duration of intubation, days (IQR) | 24.0 (50.0) | 28.0 (58.0) | 20.0 (28.0) | 0.645 |
| Severe cholestasis, n (%) | 31 (47.7%) | 22 (47.8%) | 9 (47.4%) | 0.973 |
| Cholestatic liver failure, n (%) | 15 (23.1%) | 11 (23.9%) | 4 (21.1%) | 0.803 |
| Secondary sclerosing cholangitis, n (%) | 10 (15.4%) | 8 (17.4%) | 2 (11.1%) | 0.485 |
| Decompensation/further decompensation, n (%) | 5 (7.7%) | 0 (−) | 5 (26.3%) | |
| Death, n (%) | 27 (41.5%) | 16 (34.8%) | 11 (57.9%) | 0.085 |
| COVID-19–related death, n (%) | 21 (32.3%) | 14 (30.4%) | 7 (36.8%) | 0.615 |
| Liver-related death, n (%) | 11 (16.9%) | 8 (17.4%) | 3 (15.8%) | 0.876 |

Abbreviations: ALD, alcohol-associated liver disease; ICU, intensive care unit; IQR, interquartile range; PCR, polymerase chain reaction.

*aAfter first positive SARS-CoV-2 PCR test.
**FIGURE 1**  Blood levels of hepatic aminotransferases and liver function parameters prior and during COVID-19 infection. (A) Alkaline phosphatase (ALP), (B) gamma-glutamyl transferase (GGT), (C) bilirubin, (D) aspartate aminotransferase (AST), (E) albumin and international normalized ratio (INR) in patients with liver disease and COVID-19. The borders of the whiskers are the 10th and the 90th percentile. Pre, last available value before severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2) infection; T1/T2/T3, first/second/third available value after SARS-CoV-2 infection; Last, last available value; *p < 0.050 compared to Pre.

**FIGURE 2**  Imaging features of secondary sclerosing cholangitis (SSC). (A) Coronal MIP MRCP image shows the “beaded” appearance of intrahepatic bile ducts due to alternating strictures and dilatation. A filling defect can be seen in the distal common bile duct due to stones (white arrow). (B) Coronal MIP MRCP image shows a more advanced form with poor visualization of intrahepatic bile ducts due to obliteration of peripheral ducts resulting in a “pruned tree” appearance. Stenosis at the proximal common hepatic duct is also seen (white arrow). (C) Hepatic arterial phase MRI shows inhomogeneous and wedge-shaped parenchymal enhancement (white arrows) representing edema and an increased perfusion due to focal inflammation. (D) Portal venous phase imaging on CT shows focal, intrahepatic cholangiectasis (white arrows; same patient as in A). CT, computed tomography; MIP, maximum intensity projection; MRCP, magnetic resonance cholangiopancreatography; MRI, magnetic resonance imaging.
(p = 0.455), as well as median duration of hospital stay (p = 0.417), ICU stay (p = 0.679) and intubation (p = 0.487) did not differ between patients with and without CLD. However, prevalence of death (41.5% vs. 28.8%; p = 0.037) and liver-related death (15.4% vs. 3.5%; p < 0.001) were significantly higher in patients with CLD. The impact of liver function (as assessed by MELD) and comorbidities on ICU admission rate is depicted in Table S4.

Assessed by log-rank test (p = 0.308) and Cox regression analysis (hazard ratio [HR]: 1.24; 95% confidence interval [95% CI]: 0.82–1.89; Table S5), preexisting CLD was not associated with mortality. Independent predictors of mortality in the overall cohort included older age, lower albumin, higher D-dimer and preexisting lung disease.

Clinical outcomes of patients with liver disease with and without ACLD (Table 1, Figure 2)

Importantly, 47.7% (n = 31/65) of patients with CLD exhibited severe cholestasis (ALP/GGT >5× ULN) during follow-up, and 15 patients (23.1%) with preexisting liver disease developed laboratory signs of cholestatic liver failure (severe cholestasis and BIL ≥6 mg/dl) during COVID-19. Moreover, 10 patients (15.4% of patients with CLD) were diagnosed with SSC during follow-up and one patient with preexisting primary sclerosing cholangitis showed radiological and laboratory signs of disease progression after COVID-19. Figure 2 depicts SSC-specific bile duct alterations and liver abnormalities in patients with CLD and COVID-19. Notably, there was no significant difference in frequency of cholestatic liver failure and SSC between patients with and without ACLD.

Moreover, 26.3% (n = 5/19) of patients with ACLD had a decompensation event during follow-up (ascites: n = 1, hepatic encephalopathy: n = 1 and acute-on-chronic liver failure: n = 3). Mortality was generally high among patients with CLD and COVID-19 (41.5%), but even higher in patients with ACLD (57.9%; n = 11/19; p = 0.085). There was no difference in frequency of COVID-19–related and liver-related death between patients with CLD with and without ACLD.

Comparison of clinical outcomes between patients with CLD and COVID-19 and patients with CLD and non–COVID-19 pneumonia (Table 2)

Follow-up duration (COVID-19: 59.0 days vs. non–COVID-19: 43.0 days; p = 0.166) and need for extracorporeal membrane oxygenation (ECMO; COVID-19: 20.0% vs. non–COVID-19: 18.5%; p = 0.823) did not differ between patients with CLD and COVID-19 and patients with CLD and non–COVID-19 pneumonia.

Importantly, patients with CLD and COVID-19 developed SSC more often (COVID-19: 15.4% vs. non–COVID-19: 4.6%; p = 0.040), whereas the prevalence of severe cholestasis (COVID-19: 47.7% vs. non–COVID-19: 40.0%; p = 0.376) and cholestatic liver failure (COVID-19: 23.1% vs. non–COVID-19: 21.5%; p = 0.833) did not differ compared to patients with CLD and non–COVID-19 pneumonia.

Patient characteristics and outcomes of patients with liver disease and development of SSC after SARS-CoV-2 infection (Table 3, Figure 3)

Among all 10 patients with liver disease developing SSC, five (50.0%) were male. In total, 70.0% (n = 7/10) had CLD due to NAFLD/NASH, whereas one patient had ALD, viral liver disease, and polycystic liver disease, respectively. Three patients developing SSC were 18–39 years old, whereas six patients were aged 40–69 years and one patient ≥70 years. SSC was diagnosed in two patients via ERCP and in eight patients using cross-sectional imaging. Median time from first positive SARS-CoV-2 PCR test to SSC diagnosis was 48.5 days. Median time of patients with CLD to develop cholestatic liver failure without SSC diagnosis was 43.0 (IQR 234) days, indicating that not all patients with cholestatic liver failure will progress to SSC.

Median BMI was 29.0 kg/m^2, and five patients (50.0%) were obese. In total, 60.0% (n = 6/10) had a history of arterial hypertension. All 10 patients had severe courses of COVID-19, as all of them were admitted to the ICU, nine (90.0%) required mechanical ventilation. ECMO was required in 80.0% (n = 8/10) of patients with CLD developing SSC, and 90.0% (n = 9/10) received ketamine. The lowest (median) arterial pO2 measured in patients with CLD developing SSC was clearly in the hypoxemic range with 57.6 mmHg. Most patients with SSC (9/10) were treated with ursodesoxycholic acid. Figure 2 depicts the trajectory of ALP, AST, and bilirubin in patients with CLD who developed SSC.

Median ICU stay was 69.0 days, and median duration of intubation was 75.0 days. In total, 50.0% (5/10) of patients with SSC died during follow-up and one patient was evaluated for liver transplantation.

Elevated total bilirubin after first positive SARS-CoV-2 PCR test and clinical outcomes among patients with liver disease (Table 4)

Patients with CLD with elevated bilirubin after first positive SARS-CoV-2 PCR test were more frequently
admitted to the ICU (91.7% vs. 32.1%; \( p < 0.001 \)) and intubated (91.7% vs. 26.4%; \( p < 0.001 \)), had longer median hospital stay (58.0 days vs. 21.0 days; \( p = 0.022 \)), ICU stay (47.0 days vs. 21.0 days; \( p = 0.120 \)) and intubation duration (41.0 days vs. 19.5 days; \( p = 0.047 \)). Moreover, they exhibited higher mortality (75.0% vs. 34.0%; \( p = 0.009 \)), more COVID-19–related deaths (75.0% vs. 22.6%; \( p < 0.001 \)) and more liver-related deaths (75.0% vs. 3.8%; \( p < 0.001 \)) (Figure 4).

### Table 2 Patient characteristics at the time of SARS-CoV-2 infection/pneumonia onset and outcomes of patients with chronic liver disease and COVID-19 versus non–COVID-19 pneumonia

| Patient characteristics | COVID-19 (\( n = 65 \)) | Non–COVID-19 pneumonia (\( n = 65 \)) | \( p \) value |
|-------------------------|---------------------------|------------------------------------|--------------|
| Sex, male/female (% male) | 39/26 (60.0%) | 40/25 (61.5%) | 0.857 |
| Age, years (IQR) | 67.7 (19.6) | 58.6 (25.5) | 0.002 |
| Chronic liver disease severity | | | 0.999 |
| non-ACLD | 46 (70.8%) | 46 (70.8%) | |
| cACLD | 12 (18.4%) | 12 (18.4%) | |
| dACLD | 7 (10.8%) | 7 (10.8%) | |
| Etiology | | | 0.446 |
| NAFLD/NASH, n (%) | 39 (60.0%) | 31 (47.7%) | |
| ALD, n (%) | 10 (15.4%) | 14 (21.5%) | |
| Viral hepatitis, n (%) | 5 (7.7%) | 7 (10.8%) | |
| Cryptogenic, n (%) | 3 (4.6%) | 1 (1.5%) | |
| Other, n (%) | 8 (12.3%) | 12 (18.5%) | |
| Follow-up duration, days (IQR) | 59.0 (170.0) | 43.0 (763.0) | 0.166 |
| Intubation, n (%) | 25 (38.5%) | 56 (86.2%) | <0.001 |
| Extracorporeal membrane oxygenation, n (%) | 13 (20.0%) | 12 (18.5%) | 0.823 |
| Severe cholestasis, n (%) | 31 (47.7%) | 26 (40.0%) | 0.376 |
| Cholestatic liver failure, n (%) | 15 (23.1%) | 14 (21.5%) | 0.833 |
| Secondary sclerosing cholangitis, n (%) | 10 (15.4%) | 3 (4.6%) | 0.040 |
| Death, n (%) | 27 (41.5%) | 39 (60.0%) | 0.003 |
| COVID-19/pneumonia-related death, n (%) | 21 (32.3%) | 30 (46.2%) | 0.106 |
| Liver-related death, n (%) | 11 (16.9%) | 18 (27.7%) | 0.140 |

Assessed by log-rank test, elevated levels of bilirubin (\( n = 12/65; \ p < 0.001 \)) after first positive SARS-CoV-2 PCR test were associated with shorter time to liver-related death. There was no link between liver-related mortality and elevated ALP (\( n = 31/57; \ p = 0.794 \)), GGT (\( n = 47/59; \ p = 0.126 \)), AST (\( n = 38/63; \ p = 0.106 \)) or ALT (\( n = 23/64; \ p = 0.884 \)).

Correspondingly, elevated bilirubin (HR: 3.86; 95% CI: 0.83–17.90) after first positive SARS-CoV-2 PCR test were associated with increased liver-related mortality among patients with CLD in univariate Cox regression analysis. After adjustment for potentially confounding factors, elevated bilirubin (adjusted HR [aHR]: 18.25; 95% CI: 3.94–84.52) and tendentially elevated AST (HR: 3.86; 95% CI: 0.83–17.90) after first positive SARS-CoV-2 PCR test also independently predicted liver-related related mortality among patients with CLD and COVID-19 (aHR: 1.15; 95% CI: 1.03–1.29).

### Discussion

In this study, we thoroughly characterized the patterns of liver injury and clinical outcomes of Austrian patients with CLD hospitalized for COVID-19. Importantly, we identified a biphasic pattern of liver injury in patients with CLD over the course of COVID-19, characterized by initial mild elevations of parameters of hepatocellular liver injury (AST/ALT) elevation followed by prolonged and progressive cholestasis. Almost one quarter of patients...
with CLD and COVID-19 developed laboratory signs of cholestatic liver failure, and 15.4% of patients with CLD were diagnosed with SSC. SSC development occurred almost exclusively in patients with CLD with severe courses of COVID-19 and was more frequent than in the control cohort of patients who were chronically ill with CLD with non–COVID-19 pneumonia. Moreover, patients with NAFLD/NASH and metabolic risk factors were at particular risk for SSC after COVID-19.

Overall, COVID-19–related liver injury occurred in about one quarter of patients with CLD. This is in line with previous studies reporting elevated aminotransferases (AST/ALT) in patients with liver disease and COVID-19. Although, indeed, AST/ALT elevations occurred in 60.0% of patients with CLD in our study, aminotransferase elevation was usually mild with less than 10% of patients with CLD exhibiting AST/ALT levels >3× ULN. This is in accordance with previous studies.

Furthermore, a pronounced cholestatic pattern of liver injury was common in our patients with CLD and COVID-19, particularly in later stages of the disease: although approximately 20% of patients with CLD had ALP >2× ULN already after the first positive SARS-CoV-2 PCR test, suggesting relevant cholestasis, this number almost doubled over time, which indicates sustained cholestatic alterations. Moreover, our longitudinal observation shows that ALP, as well as GGT increases over the course of COVID-19 in patients with CLD and COVID-19, whereas AST/ALT decrease following an initial peak after SARS-CoV-2 infection. This conforms to the established view of a biphasic pattern of liver injury after SARS-CoV-2 infection. Previous studies have reported elevated parameters of cholestasis in patients with CLD and COVID-19, particularly in patients with NAFLD; however, this biphasic pattern has previously not been investigated in detail in patients with CLD. Importantly, the sustained elevation of ALP in patients with CLD was still present after exclusion of patients developing SSC, indicating progressive cholestasis in patients with CLD after COVID-19.

Furthermore, laboratory signs of cholestatic liver failure were observed in 23.1% of patients with CLD, and 15.4% developed SSC. Although there are few case reports of SSC after COVID-19 the high prevalence of persistent cholestasis and SSC in patients with liver disease after COVID-19 has not yet been described. Importantly, the prevalence of SSC was significantly higher among patients with CLD and COVID-19 compared to the non-COVID pneumonia control group. This suggests that progressive cholestasis and biliary alterations are indeed distinct for COVID-19 in patients who are critically ill with CLD, as these occur more frequently than in patients with CLD without COVID-19 pneumonia.

Of note, the development of progressive cholestasis in the context of SARS-CoV-2 infection was independent of preexisting liver disease severity, as there was no difference between patients with and without ACLD. However, among the patients with COVID-19–associated SSC, there was a high prevalence of patients with obesity and/or patients with NAFLD/NASH. All patients developing SSC had severe courses of COVID-19. Notably, these patients were relatively young patients, with one third being 18–39 years old and only one patient being 70 years old or older. Seven of 10 patients with CLD developing SSC had NAFLD/NASH.

### TABLE 3 Patient characteristics at the time of severe acute respiratory distress syndrome coronavirus 2 infection and outcomes of patients with chronic liver disease and COVID-19, who developed secondary sclerosing cholangitis (SSC)

| Patient characteristics | Patients with liver disease developing SSC (n = 10) |
|-------------------------|-------------------------------------------------|
| Sex, male/female (% male) | 5/5 (50.0%) |
| Age |
| 18–39 years, n (%) | 3 (30.0%) |
| 40–69 years, n (%) | 6 (60.0%) |
| ≥70 years, n (%) | 1 (10.0%) |
| Body mass index, kg/m², median (IQR) | 26.1 (3.8) |
| Etiology |
| NAFLD/NASH, n (%) | 7 (70.0%) |
| ALD, n (%) | 1 (10.0%) |
| Viral hepatitis, n (%) | 1 (10.0%) |
| Polycystic liver, n (%) | 1 (10.0%) |
| ACLD, n (%) | 2 (20.0%) |
| Obesity, n (%) | 5 (50.0%) |
| Arterial hypertension, n (%) | 6 (60.0%) |
| Diabetes mellitus, n (%) | 3 (30.0%) |
| Dyslipidemia, n (%) | 1 (10.0%) |
| Cardiovascular disease, n (%) | 1 (10.0%) |
| Chronic renal insufficiency, n (%) | 1 (10.0%) |
| Lung disease, n (%) | 2 (20.0%) |
| Median duration to SSC diagnosis, days (IQR) | 48.5 (63.0) |
| ICU admission, n (%) | 10 (100.0%) |
| ICU stay, days, median (IQR) | 69.0 (94.0) |
| Mechanical ventilation, n (%) | 9 (90.0%) |
| Duration of mechanical ventilation, days, median (IQR) | 75.0 (66.0) |
| Extracorporeal membrane oxygenation, n (%) | 8 (80.0%) |
| Exposure to ketamine, n (%) | 9 (90.0%) |
| UDCA treatment, n (%) | 9 (90.0%) |
| Minimal arterial pO2, mmHg (IQR) | 57.6 (5.1) |
| Death, n (%) | 5 (50.0%) |

Abbreviations: ACLD, advanced chronic liver disease; ALD, alcohol-associated liver disease; ICU, intensive care unit; IQR, interquartile range.
NASH as an underlying liver disease, with high rates of obesity and arterial hypertension. Thus, it seems that development of SSC after SARS-CoV-2 infection is a relevant risk, particularly in patients with CLD with metabolic risk factors and/or NAFLD/NASH etiology.

FIGURE 3 Trajectory of blood levels of liver chemistries in patients with chronic liver disease (CLD) and COVID-19, who developed secondary sclerosing cholangitis (SSC). Panel (A) represents the median levels of ALP, AST, and bilirubin of all patients with CLD, who developed SSC, whereas panels (B–D) show the trajectory of ALP, AST, and bilirubin in exemplary patients with CLD developing SSC. Next to the course over the first 90 days after severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2) infection, the maximum value (Max), as well as the last available value (Last) are depicted. ALP, alkaline phosphatase; AST, aspartate aminotransferase; ECMO, extracorporeal membrane oxygenation; Last, last available value; Max, maximum value.

TABLE 4 Clinical outcomes of patients with chronic liver disease with and without elevated total bilirubin at COVID-19 diagnosis

| Follow-up and clinical outcomes | Bilirubin > ULN (>1.2mg/dl) (n = 12) | Bilirubin ≤ ULN (≤1.2mg/dl) (n = 53) | p value |
|--------------------------------|-----------------------------------|-----------------------------------|--------|
| Median hospital stay, days (IQR) | 58.0 (66.0) | 21.0 (35.0) | 0.022 |
| ICU admission, n (%) | 11 (91.7%) | 17 (32.1%) | <0.001 |
| Median ICU stay, days (IQR) | 47.0 (59.0) | 21.0 (24.0) | 0.120 |
| Intubation, n (%) | 11 (91.7%) | 14 (26.4%) | <0.001 |
| Median duration of intubation, days (IQR) | 41.0 (53.0) | 19.5 (25.0) | 0.047 |
| Death, n (%) | 9 (75.0%) | 18 (34.0%) | 0.009 |
| COVID-19–related death, n (%) | 9 (75.0%) | 12 (22.6%) | <0.001 |
| Liver-related death, n (%) | 9 (75.0%) | 2 (3.8%) | <0.001 |

Abbreviations: ICU, intensive care unit; IQR, interquartile range; ULN, upper limit of normal. Bold p values denote statistically significant difference.
developing SSC were treated with ketamine, which is strongly linked to drug-induced liver injury.\[39,41–43\] Furthermore, there might also be direct injury of hepatocytes and cholangiocytes by SARS-CoV-2.\[3,44\] Thus, the sustained elevation of cholestatic parameters and bile duct alterations may be explained by multifactorial liver and bile duct injury in patients who are critically ill with CLD and COVID-19. Of note, SSC takes time to develop.\[35,36\] Fittingly, patients with CLD and cholestatic liver failure who did not show signs of SSC had shorter time of follow-up, mostly due to earlier death.

Importantly, elevated bilirubin after first positive SARS-CoV-2 PCR test predicted liver-related death among patients with CLD and COVID-19. Bilirubin has been identified a valuable prognostic marker in overall cohorts of patients with COVID-19,\[22,24\] which also seems to be true in patients with COVID-19 and preexisting CLD. This is expected, as cholestasis and bilirubin elevation are known to develop in patients who are critically ill because of hepatic transport and metabolism alterations, resulting in impaired bile flow and bile acid retention.\[45–47\] Thus, bilirubin levels should be (re)assessed in patients with COVID-19 and CLD.

**FIGURE 4** Duration of hospital stay and rates of intensive care unit (ICU) admission, intubation, and death in patients with chronic liver disease and COVID-19 according to bilirubin levels. Comparison of (A) duration of hospital stay, (B) rate of ICU admission, (C) duration of ICU stay, (D) rate of mechanical ventilation, (E) rate of death, and (F) rate of liver-related death in patients with liver disease and COVID-19 with and without elevated total bilirubin (BIL ≥1.2 mg/dl) after first positive severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2) polymerase chain reaction (PCR) test. The borders of the whiskers are the 10th and the 90th percentile. Group comparison via (A, C) Mann–Whitney U test and (B, D–F) Fisher’s exact test.
CLD developing COVID-19, and those with elevated bilirubin should be closely monitored.

In line with the literature, mortality among patients with ACLD was particularly high in our cohort with 27.8% of included patients with ACLD experiencing a decompensation event during or after COVID-19. Despite high rates of mortality among patients with CLD in our cohort, CLD was not a risk factor for mortality in this study. This is probably due to the relatively small sample size of patients with CLD. Of note, well-established risk factors for mortality in patients with COVID-19 also independently predicted survival in our study.

Our study also has limitations: First, because of the retrospective study design, selection bias cannot be ruled out. Moreover, some parameters were not available at all time points. However, by only including well-characterized inpatients with COVID-19, we are confident that our data is reflective of the clinical scenario of hospitalized patients with CLD and COVID-19. Concerning Pre values, we did not discriminate, whether these values were obtained in the context of an outpatient visit or a previous hospitalization, which is a potential confounding factor. Moreover, we did not correct the Cox proportional hazard models for multiple testing, potentially impairing their reproducibility. However, the results are in line with several previous studies, identifying particularly elevated bilirubin as a predictor for poor outcome in patients with COVID-19.[18,22,24] Finally, external validation of our results is required due to our monocentric study design.

In conclusion, we observed a progressive pattern of cholestatic liver injury in a cohort of patients predominantly with NAFLD/NASH with CLD and COVID-19. About one quarter of patients with CLD and COVID-19 developed laboratory signs of cholestatic liver failure and 15.4% were diagnosed with SSC. SSC was indeed more frequent in patients with CLD who were infected with SARS-CoV-2 than in a matched control group of patients with CLD and non–COVID-19 pneumonia. Elevated bilirubin was identified as a strong risk factor for liver-related death among patients with CLD and COVID-19.

AUTHOR CONTRIBUTIONS
All authors contributed either to research design (Lukas Hartl and Thomas Reiberger) and/or the acquisition (Lukas Hartl, Katharina Haslinger, Martin Angerer, Ernst Eigenbauer, Katharina Lamplichler, Ahmed Bssalamah, and Thomas Reiberger), analysis (Lukas Hartl and Thomas Reiberger), or interpretation (all authors) of data. Lukas Hartl, Thomas Reiberger, and Michael Trauner drafted the manuscript, which was critically revised by all other authors.

CONFLICTS OF INTEREST
Dr. Simbrunner received grants from Gilead and AbbVie. Dr. Trauner consults for, is on the speakers’ bureau for, and received grants from Falk, Intercept, Gilead, and MSD. He consults for and received grants from Alberio. He consults for BiomX, Boehringer Ingelheim, Genfit, Janssen, Novartis, Shire, Phenex, and Regulus. He received grants from Cymabay, Takeda, Alnylam, Ultragenyx, and AbbVie. He is the coinventor of patents on the medical use of 24-norursodesoxycholic acid. Dr. Mandorfer consults for, advises, is on the speakers’ bureau for, and received grants from AbbVie and Gilead. He consults for, advises, and is on the speakers’ bureau for Collective Acumen and W.G. Gore & Associates.

ETHICS
The study was approved by the Ethics Committee (EC) of the Medical University of Vienna. It was performed according to the current version of the Helsinki Declaration. Due to the retrospective study design, the need for informed consent was waived by the EC.

DATA AVAILABILITY STATEMENT
Anonymized individual patient data will be made available to interested investigators at the discretion of all authors. Data requests should be sent to the corresponding author.

ORCID
Georg Semmler https://orcid.org/0000-0002-0411-166X
Mathias Jachs https://orcid.org/0000-0003-2871-4147
Benedikt Simbrunner https://orcid.org/0000-0001-8181-9146
David Josef Maria Bauer https://orcid.org/0000-0002-9363-8518
Mattias Mandorfer https://orcid.org/0000-0003-2330-0017
Bernhard Scheiner https://orcid.org/0000-0002-4904-5133
Thomas Reiberger https://orcid.org/0000-0002-4590-3583

REFERENCES
1. Atzrodt CL, Maknojia I, McCarthy RDP, Oldfield TM, Po J, Ta KTL, et al. A guide to COVID-19: a global pandemic caused by the novel coronavirus SARS-CoV-2. FEBS J. 2020;287:3633–50.
2. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324:782–93.
3. Nardo AD, Schneeweiss-Gleixner M, Bakail M, Dixon ED, Lax SF, Trauner M. Pathophysiological mechanisms of liver injury in COVID-19. Liver Int. 2021;41:20–32.
4. Doherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 2013 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;369:m1985.
5. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–62.
PROGRESSIVE CHOLESTASIS AND ASSOCIATED SCLEROSING CHOLANGITIS

6. Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020;323:1775–6.

7. Wang Y, Liu S, Liu H, Li W, Lin F, Jiang L, et al. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. J Hepatol. 2020;73:807–16.

8. Herta T, Berg T. COVID-19 and the liver - lessons learned. Liver Int. 2021;41(Suppl 1):1–8.

9. Brevini T, Maes M, Webb GJ, Gelson WTH, Forrest M, Micocchione P, et al. FXR inhibition reduces ACE2 expression, SARS-CoV-2 infection and may improve COVID-19 outcome, bioRxiv. 2021. https://doi.org/10.1101/2021.06.14.446781

10. Jothimani D, Venugopal R, Abedin MF, Kaliamoorthy I, Rela M. COVID-19 and the liver. J Hepatol. 2020;73:1231–40.

11. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.

12. Xu L, Liu J, Lu M, Yang D, Zheng X. Liver injury during highly pathogenic human coronavirus infections. Liver Int. 2020;40:998–1004.

13. Garrido I, Liberal R, Macedo G. Review article: COVID-19 and liver disease-what we know on 1st May 2020. Aliment Pharmacol Ther. 2020;52:267–75.

14. Bertolini A, van de Peppel IP, Bodewes F, Moshage H, Fantin R, et al. Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology. 2002;35:1010–21.

15. Boettler T, Marjot T, Newcombe PN, Mondelli MU, Maticic M, Cordero E, et al. Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic. JHEP Rep. 2020;2:100169.

16. Cordero E, et al. A human pluripotent stem cell-based platform to study biliary tree injury, cholangiopathy, and liver disease-what we know on 1st May 2020. Aliment Pharmacol Ther. 2020;52:584–99.

17. Parasa S, Desai M, Thoguluva Chandrasekar V, Patel HK, Kennedy KF, et al. Prevalence of gastrointestinal symptoms and fecal viral shedding in patients with coronavirus disease 2019: a systematic review and meta-analysis. JAMA Netw Open. 2020;3:e2011335.

18. Hart L, Haslinger K, Angerer M, Jachs M, Simbrunner B, Bauer DJM, et al. Age-adjusted mortality and predictive value of liver chemistries in a Viennese cohort of COVID-19 patients. Liver Int. 2022. https://doi.org/10.1111/liv.15274

19. Kulkarni AV, Kumar P, Tevethia HV, Premkumar M, Arap JB, Candia R, et al. Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19. Aliment Pharmacol Ther. 2020;52:584–99.

20. Nguyen WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–20.

21. Cai Q, Huang D, Ou P, Yu H, Zhu Z, Xia Z, et al. COVID-19 in a designated infectious diseases hospital outside Hubei Province, China. Allergy. 2020;75:1742–52.

22. Ding ZY, Li GX, Chen L, Shu C, Song J, Wang W, et al. Association of liver abnormalities with in-hospital mortality in patients with COVID-19. J Hepatol. 2021;74:1295–302.

23. Bernstein D, Roth N, Kim A, Epstein M, Hirschwerk D, Kvasnovsky CL, et al. Presentation, patterns and predictive value of baseline liver tests on outcomes in COVID-19 patients without chronic liver disease. World J Gastroenterol. 2021;27:7350–61.

24. Lei F, Liu YM, Zhou F, Qin JJ, Zhang P, Zhu L, et al. Longitudinal association between markers of liver injury and mortality in COVID-19 in China. Hepatology. 2020;72:389–98.

25. Roth NC, Kim A, Vitkovski T, Xia J, Ramirez G, Bernstein D, et al. Post-COVID-19 cholangiopathy: a novel entity. Am J Gastroenterol. 2021;116:1077–82.

26. Durazo FA, Nicholas AA, Mahaffey JJ, Sova S, Evans JJ, Trivella JP, et al. Post-Covid-19 cholangiopathy-a new indication for liver transplantation: a case report. Transplant Proc. 2021;53:1132–7.

27. Edwards K, Allison M, Ghuman S. Secondary sclerosing cholangitis in critically ill patients: a rare disease precipitated by severe SARS-CoV-2 infection. BMJ Case Rep. 2020;13:e237984.

28. Bütikofer S, Lenggenhager D, Wendel Garcia PD, Maggio EM, Haberecker M, Reiner CS, et al. Secondary sclerosing cholangitis as cause of persistent jaundice in patients with severe COVID-19. Liver Int. 2021;41:2404–17.

29. Singh S, Khan A. Clinical characteristics and outcomes of coronavirus disease 2019 among patients with preexisting liver disease in the United States: a multicenter research network study. Gastroenterology. 2020;159:768–71.e3.

30. Iavarone M, D’Ambrosio R, Soria A, Triolo M, Pugliese N, Del Poggio P, et al. High rates of 30-day mortality in patients with cirrhosis and COVID-19. J Hepatol. 2020;73:1063–71.

31. Hart L, Jachs M, Simbrunner B, Bauer DJM, Semmler G, Gompelmann D, et al. Cirrhosis-associated RAS-inflammation-coagulation axis anomalies: parallels to severe COVID-19. J Pers Med. 2021;11:1264.

32. Marjot T, Moon AM, Cook JA, Abd-Elsalam S, Aloman C, Armstrong MJ, et al. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study. J Hepatol. 2021;74:567–77.

33. Huang R, Zhu L, Wang J, Xue L, Liu Y, Yan X, et al. Clinical features of COVID-19 patients with nonalcoholic fatty liver disease. Hepatol Commun. 2020;4:1758–68.

34. Gadnson HO, Björnsson ES. Secondary sclerosing cholangitis in critically ill patients: current perspectives. Clin Exp Gastroenterol. 2017;10:105–11.

35. Jaeger C, Mayer G, Henrich R, Gossner L, Rabenstein T, May A, et al. Secondary sclerosing cholangitis after long-term treatment in an intensive care unit: clinical presentation, endoscopic findings, treatment, and follow-up. Endoscopy. 2006;38:730–4.

36. Corpechot C, Barbu V, Wendum D, Kinman N, Rey C, Poupon R, et al. Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology. 2002;35:1010–21.

37. Brenner C, Galluzzo L, Kepp O, Kroemer G. Decoding cell death signals in liver inflammation. J Hepatol. 2013;59:583–94.

38. Wong GLH, Tam YH, Ng CF, Chan AWH, Choi PCL, Chu WCW, et al. Liver injury is common among chronic abusers of ketamine. Clin Gastroenterol Hepatol. 2014;12:1759–62.e1.

39. Zangrillo A, Landoni G, Biondi-Zoccai G, Greco M, Greco T, Frati G, et al. A meta-analysis of complications and mortality of extracorporeal membrane oxygenation. Crit Care Resusc. 2013;15:172–8.

40. Lo RSC, Krishnamoorthy R, Freeman JG, Austin AS. Cholestasis and biliary dilatation associated with chronic ketamine abuse: a case series. Singapore Med J. 2011;52:e52–5.

41. Noppers IM, Niesters M, Aarts L, Bauer MCR, Drewes AM, Dahan A, et al. Drug-induced liver injury following a repeated course of ketamine treatment for chronic pain in CRPS type 1 patients: a report of 3 cases. Pain. 2011;152:2173–8.

42. Seto WK, Ng M, Chan P, Ng IO, Cheung SC, Hung IF, et al. Ketamine-induced cholangiopathy: a case report. Am J Gastroenterol. 2011;106:1004–5.

43. Yang L, Han Y, Nilsson-Payant BE, Gupta V, Wang P, Duan X, et al. A human pluripotent stem cell-based platform to study SARS-CoV-2 tropism and model virus infection in human cells and organoids. Cell Stem Cell. 2020;27:125–36.e7.
45. Horvatits T, Drolz A, Trauner M, Fuhrmann V. Liver injury and failure in critical illness. Hepatology. 2019;70:2204–15.
46. Geier A, Fickert P, Trauner M. Mechanisms of disease: mechanisms and clinical implications of cholestasis in sepsis. Nat Clin Pract Gastroenterol Hepatol. 2006;3:574–85.
47. Halilbasic E, Claudel T, Trauner M. Bile acid transporters and regulatory nuclear receptors in the liver and beyond. J Hepatol. 2013;58:155–68.

SUPPORTING INFORMATION
Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Hartl L, Haslinger K, Angerer M, Semmler G, Schneeweiss-Gleixner M, Jachs M, et al. Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID-19 in patients with chronic liver disease. Hepatology. 2022;76:1563–1575. https://doi.org/10.1002/hep.32582